Abstract |
Liver damage is one of the most common organ manifestations of chronic alcoholism. The recovery process following abstinence should not be impaired by therapy with alcohol sensitizing drugs. In a double-blind multicentre-study (controlled against placebo) the liver tolerance of Nitrefazole which is indicated as an alcohol sensitizing agent for therapy of alcoholics, was tested during the first four weeks of a planned longterm therapy. A total of 62 patients with alcoholic liver disease--demonstrated clinically and in the laboratory--were tested. The patients received 800 mg of Nitrefazole (4 capsules a 200 mg), respectively 4 placebo capsules of identical appearance, once a week in the presence of the doctor. In both treatment groups there was a significant (p less than or equal to 0.01) decline of the previously pathologically altered laboratory values, especially concerning gamma-GT, GPT, GOT. The physical and mental condition which was additionally evaluated by the doctor improved within both treatment groups. The improvement of the liver functions due to abstinence is not delayed or impaired by Nitrefazole .
|
Authors | W Feuerlein, D Heesch, L Schmidt, H P Werner, H Bethge, R Görtelmeyer |
Journal | Fortschritte der Medizin
(Fortschr Med)
Vol. 102
Issue 14
Pg. 409-13
(Apr 12 1984)
ISSN: 0015-8178 [Print] Germany |
Vernacular Title | Verträglichkeit von Nitrefazol bei leberkranken Alkoholikern. Vierwöchige Plazebo-kontrollierte Doppelblind-Studie. |
PMID | 6144620
(Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Nitroimidazoles
- gamma-Glutamyltransferase
- Aspartate Aminotransferases
- nitrefazole
|
Topics |
- Adult
- Aged
- Alcoholism
(drug therapy)
- Aspartate Aminotransferases
(blood)
- Double-Blind Method
- Drug Tolerance
- Female
- Humans
- Liver Diseases, Alcoholic
(drug therapy)
- Male
- Middle Aged
- Nitroimidazoles
(pharmacology)
- gamma-Glutamyltransferase
(blood)
|